Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390416 · ClinicalTrials.gov registry record · Phase 2
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
A Phase 2 study of Esophageal Neoplasms and Stomach Neoplasms, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT00390416 is a Phase 2 study of Esophageal Neoplasms and Stomach Neoplasms that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants, below the 1,484-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT00390416, a Phase 2 study of Esophageal Neoplasms and Stomach Neoplasms, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to find out what effects a drug named/called bevacizumab has on patients and patients' tumors when given together with standard chemotherapy drugs. Making new blood vessels seems to be important for many tumors to grow. Bevacizumab is a new type of treatment for cancer that blocks the growth of new tumor blood vessels. In this study, the researchers will combine bevacizumab with chemotherapy drugs that are standard for the patient's disease and include cisplatin, docetaxel, fluorouracil, and leucovorin. The way the original combination of cisplatin, docetaxel, and fluorouracil was given caused many side effects including gastrointestinal symptoms, weakness, and a drop in the blood count of infection fighting cells. For this study, the researchers have modified this combination to give lower doses of the medicines more often, to reduce side effects from the chemotherapy. Patients will receive bevacizumab with this modified combination of docetaxel, cisplatin, and fluorouracil. This study is called a phase II study. In this study, everyone will have similar tumors and receive the same treatment.
Conditions Studied
Interventions
- DRUG Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Study Locations (5)
New York
- Memorial Sloan-Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan-Kettering Cancer Center 1275 York Avenue - New York
- Memorial Sloan-Kettering Cancer Center at Mercy Medical Center - Rockville Centre
- Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital - Sleepy Hollow
New Jersey
- Memoral Sloan Kettering Cancer Center - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390416
The ClinicalTrials.gov registry entry for NCT00390416 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,484-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin is the first listed.
NCT00390416 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00390416 about?
NCT00390416 is a clinical study titled "Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma". This study is being done to find out what effects a drug named/called bevacizumab has on patients and patients' tumors when given together with standard chemotherapy drugs. Making new blood vessels seems to be important for many tumors to grow. Bevacizumab is a new type of treatment for cancer that ...
What is the current status of trial NCT00390416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2006-10. Estimated completion is 2012-01.
What conditions does trial NCT00390416 study?
This clinical trial studies the following conditions: Esophageal Neoplasms, Stomach Neoplasms.
What interventions are being tested in trial NCT00390416?
The interventions under investigation include: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin (DRUG).
Who is sponsoring clinical trial NCT00390416?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390416 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
COMPLETED · Phase 2
-
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
COMPLETED · Phase 2
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.